Infection remains a serious medical concern. Health Canada reports that influenza/pneumonia is one of the three most common respiratory diseases responsible for death in Canada. At the same time, the Canadian medical community is fighting a continuous battle against intra-abdominal infections, intensive care and post-operative infections, febrile neutropenia (an infection that can affect cancer patients undergoing chemotherapy) and bacterial meningitis. Canada’s health professionals – like their colleagues around the world – are also engaged in battling drug resistant bacteria.
AstraZeneca is actively involved with leading-edge research in developing the next generation of anti-infection compounds, and expects to become an even greater force in the fight against infection in the near future.
Many of our infection treatments today are used primarily in hospitals for the treatment of serious infections, ranging from hospital-acquired pneumonia and complicated urinary tract infections to pelvic inflammatory disease and bacterial septicemia.